Diamyd Medical has reached alignment with the U.S. Food and Drug Administration (FDA) to accelerate the primary efficacy readout in its ongoing pivotal, ...
As cell and gene therapies move rapidly from pioneering clinical trials into commercial healthcare systems the industry is facing a defining inflection poi...
Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company advancing small-molecule inhibition of CDC-like kinases (C...
T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food an...
Agreement addresses all requests by President Trump to reduce drug costs in the U.S., encourage global investment and protect American biopharma leader...
Eliquis® (apixaban), the Nation’s #1 Prescribed Oral Blood Thinner, Soon Available for Free to Medicaid Program Agreement Provides Tariff Re...
Measuring change in bone mineral density, rather than fracture occurrence, promises to speed development of new drugs to treat osteoporosis. FNIH Bi...
300+ advanced CT scanners to be installed in public hospitals across 38 provinces by 2028, to support early diagnosis and treatment of non-communicab...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO...
Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, today announced the s...
SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, announced the launch of two s...
Resmed , the leading health technology company focused on sleep, breathing and care delivered in the home, announced it has received U.S. Food and Drug A...
GE HealthCare and Mayo Clinic launch GEMINI-RT, a strategic initiative to personalize radiation therapy by integrating imaging, AI, and patient monit...
Investigational T-cell engager, surovatamig, and CAR T-cell therapy, AZD0120, will show potential with initial data across multiple blood cancers New ...
© 2026 Biopharma Boardroom. All Rights Reserved.
